Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pasritamig - Janssen Research & Development

Next Previous
Drug Profile

Pasritamig - Janssen Research & Development

Alternative Names: JNJ-78278343; JNJ-8343

Latest Information Update: 13 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development; Zymeworks
  • Developer Janssen; Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 07 Jan 2026 Phase-III clinical trials in Prostate cancer (Hormone refractory, Combination therapy, Metastatic disease, Second-line therapy or greater) in Taiwan (IV) (NCT07225946)
  • 07 Jan 2026 Janssen Research & Development initiates a phase III KLK2-PASenger clinical trials in Prostate cancer (Hormone refractory, Combination therapy, Metastatic disease, Second-line therapy or greater) in US (IV) (NCT07225946)
  • 30 Dec 2025 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Late-stage disease, Hormone refractory, Second-line therapy or greater) in USA (IV) (NCT0731987)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top